Partnering Teams to Optimize the Care of Patients With HER2-Positive Breast Cancer∗

Partnering Teams to Optimize the Care of Patients With HER2-Positive Breast Cancer∗

Bibliographic Details
Main Author:	Erica L. Mayer, MD, MPH
Format:	Article
Language:	English
Published:	Elsevier 2020-06-01
Series:	JACC. CardioOncology
Subjects:	breast cancer HER2 trastuzumab
Online Access:	http://www.sciencedirect.com/science/article/pii/S266608732030082X

Similar Items

Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective
by: Michelle Bradbury, et al.
Published: (2023-12-01)

Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review
by: Julie Lebert, et al.
Published: (2022-04-01)

First line chemotherapy plus trastuzumab in metastatic breast cancer HER2 positive - Observational institutional study
by: Meryem Aitelhaj, et al.
Published: (2016-08-01)

Cardiac Safety of Trastuzumab on 185 Patients with HER2 Positive Breast Cancer
by: MENG Wenjing, et al.
Published: (2018-02-01)

Combination of Pertuzumab and Trastuzumab in the Treatment of HER2-Positive Early Breast Cancer: A Review of the Emerging Clinical Data
by: Jagosky M, et al.
Published: (2021-06-01)

Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
by: Michela Piezzo, et al.
Published: (2021-05-01)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
by: Yoshiya Horimoto, et al.
Published: (2022-03-01)

Neoadjuvant systemic therapy of HER2-positive breast cancer
by: M A Frolova
Published: (2015-12-01)

Triple HER2-blockade with lapatinib, trastuzumab, and pertuzumab for treatment of HER2 positive metastatic breast cancer with lymphangitic carcinomatosis: A case study
by: Kazuki Nozawa, et al.
Published: (2022-09-01)

Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
by: Volkmar Müller, et al.
Published: (2018-03-01)

How I treat HER2-low advanced breast cancer
by: Ilana Schlam, et al.
Published: (2023-02-01)

Trastuzumab Provides a Comparable Prognosis in Patients With HER2-Positive Breast Cancer to Those With HER2-Negative Breast Cancer: Post Hoc Analyses of a Randomized Controlled Trial of Post-Mastectomy Hypofractionated Radiotherapy
by: Guang-Yi Sun, et al.
Published: (2021-01-01)

Do all patients with HER2 positive breast cancer require one year of adjuvant trastuzumab? A systematic review and meta-analysis
by: Paul Stewart, et al.
Published: (2020-12-01)

Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer
by: Babak Nami, et al.
Published: (2018-09-01)

A case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy after primary treatment of triple-negative breast cancer
by: Haruta Rumi, et al.
Published: (2011-11-01)

Omics and immunologic approaches to optimizing cure rates in HER2-positive breast carcinomas.
by: Elda eTagliabue, et al.
Published: (2014-11-01)

Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
by: Hiromichi Nakajima, et al.
Published: (2022-02-01)

A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer
by: Iain R. Macpherson, et al.
Published: (2019-12-01)

The Exciting New Field of HER2-Low Breast Cancer Treatment
by: Daniel Eiger, et al.
Published: (2021-03-01)

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
by: Fei Xing, et al.
Published: (2023-01-01)

Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies
by: Alejandro Garcia-Alvarez, et al.
Published: (2021-06-01)

Mild Cardiotoxicity and Continued Trastuzumab Treatment in the Context of HER2-Positive Breast Cancer
by: Orianne de la Brassinne Bonardeaux, et al.
Published: (2023-10-01)

Change in HER-2/neu Status from Negative to Positive following Treatment in Breast Cancer: A Case Report
by: Lakshmi Sivarajan, et al.
Published: (2011-01-01)

Strategy and Status of Neoadjuvant Therapy for HER2-positive Breast Cancer
by: LIU Yunjiang, et al.
Published: (2024-01-01)

Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents
by: Zhen-hao Wang, et al.
Published: (2022-10-01)

Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends
by: Kreina Sharela Vega Cano, et al.
Published: (2022-12-01)

What if the future of HER2‐positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study
by: Sara Pizzamiglio, et al.
Published: (2022-01-01)

HER2-Low Breast Cancer: Current Landscape and Future Prospects
by: Shirman Y, et al.
Published: (2023-08-01)

Controversies of radiotherapy in human epidermal growth factor receptor (HER)-2 positive breast cancer patients
by: Iveta Kolarova, et al.
Published: (2021-03-01)

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
by: Luai S. Al Rabadi, et al.
Published: (2021-10-01)

Neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer
by: Nadia Harbeck
Published: (2022-03-01)

MZ1 co-operates with trastuzumab in HER2 positive breast cancer
by: María del Mar Noblejas-López, et al.
Published: (2021-03-01)

A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast Cancer
by: Ricardo Fernandes, et al.
Published: (2023-08-01)

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial
by: Maria Vittoria Dieci, et al.
Published: (2019-11-01)

Dual anti-HER2 blockade in late-line treatment of metastatic HER2-positive breast cancer
by: M. A. Frolova, et al.
Published: (2021-12-01)

Adjuvant application of trastuzumab in HER2 positive breast cancer and impact on time to relapse
by: Dukić Nikolina, et al.
Published: (2020-01-01)

HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trialResearch in context
by: Valentina Guarneri, et al.
Published: (2022-11-01)

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
by: Giulia Bon, et al.
Published: (2020-12-01)

An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction
by: İrfan Cicin, et al.
Published: (2022-01-01)

Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis
by: Wu Y, et al.
Published: (2018-09-01)